Fluid-based phaco outperforms ultrasound

Article

Performing cataract surgery using a fluid-based method of phacoemulsification results in less corneal endothelial cell loss compared with conventional ultrasound phacoemulsification.

Performing cataract surgery using a fluid-based method of phacoemulsification results in less corneal endothelial cell loss compared with conventional ultrasound phacoemulsification, according to a report published in the January issue of Cornea.

Jêrôme Richard MD and colleagues from France, compared in vivo corneal endothelial cell loss from phacoemulsification performed with the Alcon Infiniti vision system using either AquaLase or conventional ultrasound. The study included 42 eyes of 42 patients who were randomly assigned to undergo surgery with one of the two modalities. In each case, surgeons used the divide-and-conquer technique through a 3.2 mm clear corneal incision and capsular bag intraocular lens (IOL) implantation.

Preoperatively, both groups had similar nuclear opalescence, averaging 4.5 on the LOCS III scale and only eyes with cataracts of nuclear opalescence graded up to 4.9 were included.

At one-week follow-up, endothelial cell loss averaged 498 cells/mm2 (20.6%) in the ultrasound group and 302 cells/mm2 (22.9%) in the fluid-based group. At one-month, endothelial cell loss averaged 589 cells/mm2 (24.3%) and 254 cells/mm2 (11.2%) in the ultrasound and fluid-based groups, respectively and at three-months follow-up, cell loss averaged 555 cells/mm2 (22.9%) and 247 cells/mm2 (10.9%) in the ultrasound and fluid-based groups, respectively.

The researchers concluded that fluid-based phacoemulsification results in significantly less endothelial cell loss than traditional ultrasound techniques.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.